subscribeSubscribe
Blueprint Reports Strong Q1 2024, Raises AYVAKIT® Revenue Guidance

Blueprint Reports Strong Q1 2024, Raises AYVAKIT® Revenue Guidance
PR NEWSWIRE
02 May 2024
Share Share
Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data

Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data
PR NEWSWIRE
23 Feb 2024
Share Share
Blueprint boosts Ayvakit peak sales estimate to $2B

Blueprint boosts Ayvakit peak sales estimate to $2B
FIERCE PHARMA
15 Feb 2024
Share Share
EC approves treatment for rare haematological disorder

EC approves treatment for rare haematological disorder
EUROPEAN PHARMACEUTICAL REVIEW
13 Dec 2023
Share Share
Blueprint Medicines` AYVAKYT® (avapritinib) Receives Positive CHMP Opinion

Blueprint Medicines` AYVAKYT® (avapritinib) Receives Positive CHMP Opinion
PR NEWSWIRE
10 Nov 2023
Share Share
QIAGEN receives FDA approval for companion diagnostic to Blueprint™ AYVAKIT

QIAGEN receives FDA approval for companion diagnostic to Blueprint™ AYVAKIT
GLOBENEWSWIRE
07 Aug 2023
Share Share
FDA Approves AYVAKIT as Only Treatment for Indolent Systemic Mastocytosis

FDA Approves AYVAKIT as Only Treatment for Indolent Systemic Mastocytosis
PR NEWSWIRE
23 May 2023
Share Share
Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label

Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label
Lei Lei Wu ENDPTS
27 Feb 2023
Share Share
Blueprint lays out $1.5B expansion plan for Ayvakit

Blueprint lays out $1.5B expansion plan for Ayvakit
Angus Liu FIERCE PHARMA
18 Feb 2023
Share Share
Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting

Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
PRESS RELEASE
04 Feb 2023
Share Share